TIGERMED (03347.HK): buyback reaches 20.96m shares, RMB 824m
- The repurchased shares represent 2.4347% of total share capital and 2.8410% of A-share capital.
- The plan allows RMB 500 million to RMB 1 billion at no more than RMB 60 per share over 12 months.
NewTimeSpace News: On 3 November 2026, Hangzhou Tigermed Consulting Co., Ltd. (stock code: 03347) published an overseas regulatory announcement under Rule 13.10B. As at 30 October 2026, it had repurchased 20,963,478 A-shares through its dedicated account by centralised bidding, equal to 2.4347% of total share capital and 2.8410% of A-share capital, for RMB 824,339,556.29 excluding transaction costs.
The highest and lowest prices paid were RMB 42.78 and RMB 38.22 per share. The plan, approved by the board on 13 May 2026 and by shareholders on 9 June 2026, provides for RMB 500 million to RMB 1 billion at no more than RMB 60 per share over 12 months. The shares will fund equity incentives or employee shareholding and be cancelled to reduce registered capital. The Company said the timing, volume, method and order periods complied with Shenzhen exchange rules.
- TIGERMED (03347.HK): Controlling Shareholders Ye Xiaoping and Cao Xiaochun Receive Warning Letter and Administrative Penalty Pre-notice Over Shareholding-change Disclosure Violations; RMB 1 Million Fine Proposed
- Tigermed (03347.HK): Has repurchased A-shares with a total consideration of approximately RMB 824 million
- TIGERMED(03347.HK) will spend CNY 175.37 million to repurchase 4.44 million shares on Jun 12, 2026
- TIGERMED (03347.HK): Directors and Controlling Shareholders Ye Xiaoping and Cao Xiaochuan Placed Under CSRC Investigation
- HS Optimus Holdings Proposes SGD4.2 Million Acquisition of 30% Stake in Medicorp Plus Put Option for Additional 19% Equity
